WADA prohibited list is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-23. Numbers and descriptions here follow the published literature rather than marketing material.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
== Mechanism == As previously mentioned, BCKDC's primary function in mammals is to catalyze an irreversible step in the catabolism of branched-chain amino acids. However BCKDC has a relatively broad specificity, also oxidizing 4-methylthio-2-oxobutyrate and 2-oxobutyrate at comparable rates and with similar Km values as for its branched-chain amino acid substrates. The BCKDC will also oxidize pyruvate, but at such a slow rate this side reaction has very little physiological significance. The reaction mechanism is as follows. Please note that any of several branched-chain α-ketoacids could have been used as a starting material; for this example, α-ketoisovalerate was arbitrarily chosen as the BCKDC substrate.
== Achievements == Lee is best known for his research in capillary separations and mass spectrometry detection. He is an author or co-author of over 550 scientific publications. Among the scientific awards that he has received for his achievements in research and professional activities are the M.S. Tswett Chromatography Medal (1984), the Keene P. Dimick Chromatography Award (1988), the American Chemical Society Award in Chromatography (1988), the Russian Tswett Chromatography Medal (1992), the Martin Gold Medal (1996), the Latin-American Chromatography Congress Medal (1998), the M.J.E. Golay Award (1998), the American Chemical Society Award in Chemical Instrumentation (1998), an honorary doctorate from Uppsala University in Sweden (1998), the Dal Nogare Award (1999), the Eastern Analytical Symposium Award for Achievements in Separation Science (1999), the California Separation Science Society Award (2005), the Pittsburgh Analytical Chemistry Award (2008), R&D 100 Awards (1993, 2008), Eastern Analytical Symposium Award for Outstanding Achievements in the Fields of Analytical Chemistry (2008), the American Chemical Society Award in Separations Science and Technology (2012), and the LC/GC Europe Lifetime Achievement Award (2014). He is also an entrepreneur and has been involved in transferring technology from his university research laboratory to the private sector.
== Side effects == Adverse events are generally caused by incorrect dosing. Long-term suppression of TSH values below normal values frequently causes cardiac side effects and contributes to decreases in bone mineral density (low TSH levels are also well known to contribute to osteoporosis). Too high a dose of levothyroxine causes hyperthyroidism. Overdose can result in heart palpitations, abdominal pain, nausea, anxiety, confusion, agitation, insomnia, weight loss, and increased appetite. Acute massive overdose may be life-threatening; treatment should be symptomatic and supportive. Massive overdose can be associated with increased sympathetic activity, thus may require treatment with beta blockers. The effects of overdosing appear 6 hours to 11 days after ingestion.
==== England (1920, 1923, 1925, 1935, 1938, 1946) ==== Constance Long arranged for Jung to deliver a seminar in Cornwall in 1920. Another seminar was held in 1923, this one organized by Jung's British protégé Helton Godwin Baynes (known as "Peter") (1882–1943), and another in 1925.
=== Patents === In 1913 Pennington and Howard Castner Pierce were issued a U.S. patent for an all-metal poultry-cooling rack for the cooling and grading of poultry, rabbits, and game. In 1927 she and Alex Brooking Davis were issued a U.S. patent for the manufacture of strawboard. In 1932 she was issued a U.S. patent for a scale for determining the color of egg meat. In 1935 she and Arthur W. Thomas were issued a U.S. patent for a method of treating eggs. Later in 1935, she was issued a U.S. patent for a method for freezing eggs.
Sources: en.wikipedia.org
A contradiction of this theory is that syndicates had developed long before large-scale Sicilian immigration in the 1860s, with these immigrants merely joining a widespread phenomenon of crime and corruption.
The secret behind a spider web's stickiness lies in the tiny glue droplets dotting its silk threads. Orb-weaver spiders, such as Larinioides cornutus, coat their silk with a special hygroscopic substance that keeps the glue soft and tacky by drawing in water from the air. This built-in humidity control prevents the adhesive from drying out too quickly. The hardening of the viscoelastic protein is indirectly controlled by changes in water content, which in turn affect the concentration of the ionic liquid. As this balance shifts, the glue's viscosity adjusts, helping the web maintain its grip on captured prey. The web is electrically conductive which causes the silk threads to spring out to trap their quarry, as flying insects tend to gain a static charge which attracts the silk. Neurotoxins have been detected in the glue balls of some spider webs. Presumably these toxins help immobilize prey, but their function could also be antimicrobial, or protection from ants or other animals that steal from the webs or might attack the spider. Spider silk has greater tensile strength than the same weight of steel and much greater elasticity. Its microstructure is under investigation for potential applications in industry, including bullet-proof vests and artificial tendons. Researchers have used genetically modified mammals and bacteria to produce the proteins needed to make this material.
== Production == Optimer ligands are produced via solid-phase synthesis. Solid-phase chemical synthesis was invented in the 1960s by Robert Bruce Merrifield, for which he was awarded the Nobel Prize for Chemistry in 1984. Solid-phase synthesis is carried out on a solid support held between filters, in columns that enable all reagents and solvents to pass through freely. Solid-phase synthesis has a number of advantages over cell-based manufacturing that is typically used for protein affinity reagents, such as antibodies:
== History == IDLO was founded in 2016 to create tasty, healthy, and convenient meals for mountain hiking and expeditions. IDLO was the first company in Ukraine to package freeze-dried meals in doypacks, allowing users to prepare and consume meals directly from the pouch without the need for dishes. Its range of main courses is produced using freeze-drying technology at its facility, in accordance with food safety management systems compliant with ISO 22000/HACCP standards. Since 2020, the company has been supplying freeze-dried meals to the Ukrainian Antarctic research station Academician Vernadsky. The company's product line includes over 40 items, such as breakfasts, lunches, dinners, snacks, and beverages. Products are available in retail chains including Gorgany, Decathlon, and Intersport/Epicentr.
=== Treatment by family, friends, or co-workers === Family, friends, and co-workers of those with hypoglycemia are often first to identify hypoglycemic episodes, and may offer help. Upon recognizing the signs and symptoms of hypoglycemia in a diabetic, a blood sugar level should first be measured using a glucose meter. If blood glucose is below 70 mg/dL (3.9 mmol/L), treatment will depend on whether the person is conscious and can swallow safely. If the person is conscious and able to swallow, the family, friend, or co-worker can help hypoglycemic consume 10–20 grams of a carbohydrate to raise blood glucose levels to a minimum of 70 mg/dL (3.9 mmol/L), using the same general procedures as for self-treatment (see the previous section). If the person is unconscious, a glucagon kit may be used to treat severe hypoglycemia, which delivers glucagon either by injection into a muscle or through nasal inhalation. In the United States, glucacon kits are available by prescription for diabetic patients to carry in case of an episode of severe hypoglycemia. Emergency services should be called for further assistance.
Sources: en.wikipedia.org
=== Peru === Joseph Dombey, in a letter written from Lima on 20 May 1779, specifies the ancestral way used by the Peruvians to prepare potatoes that constitute, along with maize (U.S.: "corn"), their primary foods. Further, that they carry potatoes in haversacks on long journeys, for which the potato is prepared by cooking it in water, then peeling it, and finally exposing it to the wind and sun until it has completely dried. The process can preserve it "several centuries, by guaranteeing it of the humidity". This papa seca (dried potato) is then mixed in with other foods to make meals. Another process consists of freezing the potato and treading on it to remove the skin. Thus prepared, it is put in running water and loaded with stones. Fifteen or twenty days later, it is exposed to the sun until it dries. It becomes the chuño, "a real starch, with which one could make powder for the hair". The Peruvians use it to prepare jams, a flour for convalescents, and mix it with almost all their dishes. An author of the 20th century points out that the process of the Peruvians, who operate by freezing followed by dehydration, is none other than "a freeze-drying by the natural means". He specifies that the tubers are left in frozen water several nights before being exposed to the sun and trodden on and that, "to make the product suitable for consumption, it is enough to put it back in water". According to him, the Spaniards used this preparation in the 16th century to feed the indigenous people forced to work in the silver mines of Potosi.
Beyond Tough, a 2002 documentary series, aired on Discovery Channel about the world's most dangerous and intense professions, such as alligator wrestlers and Indy 500 pit crews, was hosted by Ice-T. In 2007, Ice-T appeared as a celebrity guest star on the MTV sketch comedy show Short Circuitz. Also in late 2007, he appeared in the short-music film Hands of Hatred, which can be found online.
Glycolipid transfer protein is a cytosolic protein that catalyses the transfer of glycolipids between different intracellular membranes. It was discovered by Raymond J. Metz and Norman S. Radin in 1980 and partially purified and characterized in 1982. Recent reviews on structure and possible function are available. This protein transports primarily different glycosphingolipids and glyceroglycolipids between intracellular membranes, but not phospholipids. It might be also involved in translocation of glucosylceramides. It was found in brain, kidney, spleen, lung, cerebellum, liver and heart.
=== Mentor === Hodgkin's mentor Professor John Desmond Bernal greatly influenced her life: scientifically, politically, and personally. Bernal was a key scientific adviser to the UK government during the Second World War. He was also an open and vocal member of the Communist Party and a faithful supporter of the Soviet regime until its invasion of Hungary in 1956. He was a chemist who believed in equal opportunity for women. In his laboratory, Hodgkin extended work that he began on biological molecules including sterols. She helped him to make the first X-ray diffraction studies of pepsin and crystalline protein. Hodgkin always referred to him as "Sage". They were lovers before she met Thomas Hodgkin. The marriages of both Dorothy and Bernal were unconventional by the standards of the present and of those days.
=== Operation Iraqi Freedom, 2006–2009, "The Surge" === In December 2006, 2nd BCT deployed once again to Iraq in support of OIF. On 4 January 2007, 2nd Brigade deployed to northern Bagdad in the Sumer and Talbiyah district, returning 8 March 2008. On 4 June 2007, 1st Brigade deployed to Southern Iraq, returning 15 July 2008. Since the deployment began, the division has lost 37 paratroopers. Since 11 September 2001, the division has lost 20 paratroopers in Afghanistan and 101 paratroopers in Iraq.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.